Skip to content
by Legal Desire
SIGN IN GO PRO
Lawyer profile

John Manthei

Latham & Watkins LLP
Claim this profile
Firm
Latham & Watkins LLP
Practice
FDA regulatory, FDA/regulatory, healthcare & life sciences matters
Office
Washington D.C., Washington, D.C.
Active in the record
2020 to 2026

Deal experience

Deal types
Capital Markets & IPODebt Capital MarketsM&A
Sectors
Healthcare & Life Sciences
Jurisdictions
United States

Recent deals

13 announced deals in the record
Latham & Watkins Represents AtaiBeckley in Sale to Lilly 17 Jul 2026
M&A Healthcare & Life Sciences Latham & Watkins LLP FDA/regulatory
Latham & Watkins Advises IDEAYA Biosciences on US$300 Million Offering of Common Stock and Pre‑Funded Warrants 11 Jun 2026
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 300m FDA regulatory Washington, D.C.
Latham & Watkins Advises Revolution Medicines in Upsized US$750 Million Public Offering of Common Stock and Pre-Funded Warrants 5 Dec 2024
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 750m regulatory Washington, D.C.
Latham & Watkins Advises Laminar, Inc. in US$400 Million Acquisition by Johnson & Johnson Medtech 6 Dec 2023
M&A Healthcare & Life Sciences Latham & Watkins LLP USD 400m FDA regulatory Washington, D.C.
Latham & Watkins Advises IDEAYA Biosciences in Public Offering 2 Nov 2023
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 144m FDA regulatory Washington, D.C.
Latham & Watkins Advises IDEAYA Biosciences in Pricing of Public Offering 26 Apr 2023
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 175m FDA regulatory Washington, D.C.
Latham & Watkins Advises Revolution Medicines in its US$300.0 Million Public Offering of Common Stock 6 Mar 2023
Capital Markets & IPO Latham & Watkins LLP USD 300m regulatory Washington, D.C.
Latham & Watkins Advises AcuFocus in Acquisition by Bausch + Lomb 19 Jan 2023
M&A Healthcare & Life Sciences Latham & Watkins LLP FDA regulatory Washington, D.C.
Latham & Watkins Advises Opiant Pharmaceuticals in Sale to Indivior PLC 15 Nov 2022
M&A Healthcare & Life Sciences Latham & Watkins LLP USD 20 FDA regulatory Washington D.C.
Latham & Watkins advises Revolution Medicines in its US$230 Public OfferingMillion 20 Jul 2022
Capital Markets & IPO Latham & Watkins LLP USD 230m regulatory Washington, D.C.
Free account

6 more recent deals

Create a free account to see every deal team member, full deal lists on firm and lawyer pages, and to claim your profile.

REGISTER FREE SIGN IN
Deal alerts PRO

Get an email when John Manthei is named on a newly announced deal.

See Pro plans

Alerts come as one daily email at most.

Free account

Register free to unlock

  • Every lawyer on every deal team, not just the first three
  • The full recent-deal list on lawyer pages
  • Claim and edit your own firm or lawyer profile
  • Submit deals and corrections
  • Request a Pro trial for your team
REGISTER FREE Sign in

You have a free account. Everything in this column is open to you.

Pro

Get Pro to see all 13 deals for John Manthei

  • Complete deal history with keyword, type, sector and year filters
  • Frequent co-counsel and the firms most often on the other side
  • Repeat clients, as named in the announcements
  • Market share and deals by year, sector and deal type
  • Deal alerts by firm, lawyer, sector, deal type or jurisdiction
  • CSV and Excel export, up to 1,000 rows a day, and custom reports
GET PRO How Pro works
Is this you?

Claim your profile to add your title, a biography and a photo, and show a verified badge. It is free.

Claim this profile

Suggest a correction